# Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

> **NCT04768296** · PHASE2 · COMPLETED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 76 (actual)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** Berzosertib
- **DRUG:** Berzosertib
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT04768296
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-29
- **Primary completion:** 2023-07-21
- **Final completion:** 2023-07-21
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2024-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04768296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04768296, "Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04768296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*